Abstract: The present invention relates to a process for preparing a polyol ether of formula (I), comprising a step of reductive alkylation involving a compound of general formula (II) and a compound of general formula (III): in which R1, R2, R3 and R4 are as defined in claim 1.

Abstract: Disclosed is a method for preparing, by transcarbonation, a compound of formula (I), including reacting a polyol of formula (II) with an alkyl carbonate or an alkylene carbonate in the presence of a catalytic system consisting of a catalytic entity selected from among the rare earth oxides or the mixtures thereof, and optionally an inert substrate.

Abstract: A process which allows separation of americium present in an acid aqueous phase or in an organic phase from the other metal elements also found in this phase, by complexation of the americium with a water-soluble ethylenediamine derivative; and a process for selective recovery of americium from an acid aqueous phase containing, in addition to americium, other metal elements, which comprises the application of this separation process.

Abstract: The present invention relates to a new and competitive process for the preparation of 4-amino-5-hexenoic acid and intermediates thereof. The compound, and compositions containing the compound as an active ingredient, can be used for the treatment and/or prophylaxis of epilepsy and West syndrome.

Abstract: The present invention relates to a method for preparing carboxylic acids, in particular mono- and dicarboxylic acids, by oxidative cleavage of a vicinal diol. According to the invention, said method consists of reacting a vicinal diol of formula I: where: p is an integer comprised between 1 and 6; R1 and R2 are, separately: an alkyl or hydroxyl group having 1 to 12 carbon atoms; a —(CH2)n—C02M group where n, which can be identical or different in R1 and R2, is an integer comprised between 1 and 11 and M is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms or an alkaline cation; or R1 and R2 jointly form an alkylene —(CH2)m- group where m is an integer comprised between 2 and 10, preferably between 2 and 6; with industrial-grade sodium hypochlorite (or bleach), in the absence of an organic solvent and without adding a catalyst, preferably at room temperature. The invention can be used for recycling natural vegetable oils.

Abstract: The invention relates to a gaseous composition containing an effective amount of argon gas for use, by inhalation, in preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it contains between 15 and 80% by volume of argon, and oxygen, preferably at least 21% by volume of oxygen. The organ deficiency or failure thus treated is transient, preferably from less than one hour to a plurality of days or weeks, or definitive. The organ concerned may be the liver, the kidneys or the lungs.

Abstract: This invention relates to novel coumarin derivative, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.

Abstract: The invention relates to a liquid formulation including a liquid solution and at least one gas selected from xenon, argon, hydrogen, H2S, helium, krypton, neon, radon or CO, said gas being dissolved in said liquid solution, for the use thereof as a preservative solution for preserving biological material, in particular cells, tissue and biological organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the intestines. The gas is preferably argon.

Abstract: This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds.

Abstract: The invention relates to a process for separating, in an aqueous medium, at least one actinide element from one or more lanthanide elements by using at least one molecule which sequesters the said actinide element to be separated and membrane filtration, the said process successively comprising: a) a step of bringing at least one molecule which sequesters the said actinide element in contact with the aqueous medium, the said molecule not being retained in the non-complexed state by the said membrane and being capable of forming a complex with the actinide element to be separated, comprising the said element and at least two of the said sequestering molecules, which complex is capable of being retained by the membrane; b) a step of passing the aqueous medium over the membrane in order to form a permeate on one side, comprising an aqueous effluent depleted of the said actinide element, and a retentate comprising the said complex.

Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: A process for the separation and purification of hafnium and zirconium.

Abstract: A process in which isotopes of the same element belonging to the alkaline earth metals, transition elements and heavy metals having an atomic mass of less than 209, in particular lanthanide metals, are separated in an aqueous medium by treating an aqueous medium.

Abstract: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen.

Abstract: A method for separating zirconium and hafnium from a mixture of ZrCl4 and HfCl4 containing 3 wt. % or less of Hf based on Zr+Hf, the method includes the following steps: 1) hydrolyzing a mixture of ZrCl4 and HfCl4 in an aqueous solution of strong inorganic acid, so as to form an aqueous solution having 7 to 12 moles of acid per liter; 2) passing the solution obtained at step 1) in an anion exchanging resin; 3) optionally eluting a fraction of said aqueous solution having 7 to 12 moles of acid per liter, enriched in hafnium; 4) removing the resin of the acid solution containing Zr and Hf; 5) passing in the resin an aqueous solution to detach the zirconium compounds fixed to the resin, and recovering a zirconium-enriched fraction.

Abstract: A process for the separation and purification of hafnium and zirconium.

Abstract: The invention relates to a process for separating, in an aqueous medium, at least one actinide element from one or more lanthanide elements by using at least one molecule which sequesters the said actinide element to be separated and membrane filtration, the said process successively comprising: a) a step of bringing at least one molecule which sequesters the said actinide element in contact with the aqueous medium, the said molecule not being retained in the non-complexed state by the said membrane and being capable of forming a complex with the actinide element to be separated, comprising the said element and at least two of the said sequestering molecules, which complex is capable of being retained by the membrane; b) a step of passing the aqueous medium over the membrane in order to form a permeate on one side, comprising an aqueous effluent depleted of the said actinide element, and a retentate comprising the said complex.

Abstract: A novel method of reducing a functional group in an oxidised form. The invention relates more particularly to the reduction of aldehyde, ketone, ester, lactone, nitrile or phosphine oxide groups. The reduction method according to the invention is characterised in that it comprises exposing the substrate including the functional group to be reduced to the presence of a siloxane-type compound of the following formula (I), combined with a Lewis acid-type catalyst. In said formula (I):—R1 and R2, which are the same or different, are an alkyl, cycloalkyle or aryl group, —X is a digit from 0 to 50.

Abstract: A medicinal composition and method to treat or minimize post-ischemic brain cell deterioration that comprises nitrous oxide or a nitrous oxide donor and xenon or a xenon donor. The medicinal composition may be administered prior to or subsequent to a stroke.

Abstract: A process in which isotopes of the same element belonging to the alkaline earth metals, transition elements and heavy metals having an atomic mass of less than 209, in particular lanthanide metals, are separated in an aqueous medium by treating an aqueous medium.